J&J's NEW R. W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
J&J's NEW R. W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE will consolidate the drug R&D efforts of Ortho, McNeil, Cilag and the Johnson & Johnson Biotech Center, centralizing activities under one management group. The announcement was made at the company's annual shareholders' meeting April 28 by Executive Committee Vice Chairman Robert Wilson, who has overall responsibility for the firm's pharmaceutical business. A search is currently under way to find a top executive to serve as president of the R. W. Johnson Research Institute. J&J explained the establishment of the new institute as a move to coordinate R&D efforts. With an initial operating budget of about $ 200 mil., the new research institute will be headquartered in either the Raritan or Sommerville area of New Jersey. However, the different pharmaceutical divisions will continue to operate existing research facilities -- Ortho in Raritan, McNeil in Spring House, Pennsylvania, Cilag in Switzerland and J&J Biotech in La Jolla, California. Not included in the reorganization is the Belgium-based Janssen Research Foundation, which will remain separate.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.